GNUS
Genius Brands International Inc
-61.31%
$6.54 - $2.53
Feb 8th 2023 - Mar 22nd 2023
Jan, 20, 2023
GNUS GNUS ⚠️ 📢 🚨 ANALYSTS PT OF $5 SHARE THIS ⚠️ 📢 🚨 ⚠️
Jan, 20, 2023
$HTGM primed for $10+: STRONG BUY signal 700K flo... See more
SQ
Block Inc
-6.88%
$83.18 - $77.46
Feb 7th 2023 - Mar 21st 2023
Jan, 11, 2023
Analysts believe the worst may be over regarding negative sentiment.
Dec, 27, 2022
$SQ Analysts are starting to build traction for SQ... See more
TGTX
TG Therapeutics Inc
-19.05%
$18.43 - $14.92
Feb 7th 2023 - Mar 21st 2023
Dec, 30, 2022
The analyst comments "TGTX stock is up >15... See more
Dec, 30, 2022
Ignorant analyst are a plus.
Jan, 20, 2023
GNUS GNUS ⚠️ 📢 🚨 ANALYSTS PT OF $5 SHARE THIS ⚠️ 📢 🚨 ⚠️
Jan, 20, 2023
$HTGM primed for $10+: STRONG BUY signal 700K float 500%+ Cost to Borrow $3M MC w/ $14M in cash Recent analyst targets of $15.00+ Excellent technical setup Also watching: $WISA $SLRX $GNUS
Jan, 11, 2023
Analysts believe the worst may be over regarding negative sentiment.
Dec, 27, 2022
$SQ Analysts are starting to build traction for SQ, which has a compelling value proposition from these (2018) levels, IMO.
Nov, 28, 2022
$RIVN $SQ $RBLX $LCID Best analyst price target today.
Nov, 4, 2022
$SQ makes sense, they beat earnings and analysts lower price predictions.
Dec, 30, 2022
The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,
Dec, 30, 2022
Ignorant analyst are a plus.
Dec, 30, 2022
This stock would go far beyond analysts Price Target.
Dec, 30, 2022
$TGTX , absolutely amazing….Scumbag’s Bank of America analyst rated TG today as underperform $6….total joke….I guess the analyst is waiting for FDA approval…LOL ….stick to loans and mortgages….very bullish TG community Longs….
Dec, 29, 2022
The analyst comments "TGTX stock is up >15% (versus +4% for XBI) driven by: 1) positive comments on pricing: we think list price is rational with some discount vs. Ocrevus to lower cost burden and get broad access,